Study of Combination Communication Regime
Sign Up to like & getrecommendations! Published in 2022 at "IEEE Access"
DOI: 10.1109/access.2022.3183595
Abstract: In this paper, to the best of our knowledge, we propose a comprehensive combination communication regime for the first time, which uses the spatial position combination of different physical entities, rather than the change of… read more here.
Keywords: communication; combination; combination communication; communication regime ... See more keywords
A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps2616
Abstract: TPS2616Background: Spartalizumab is an immunoglobulin G4 humanized monoclonal antibody that binds with subnanomolar affinity to PD-1. LAG525 is an immunoglobulin G4 humanized monoclonal antibody th... read more here.
Keywords: combination spartalizumab; study combination; lag525; phase open ... See more keywords
A Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.11507
Abstract: 11507Background: For advanced LPS and LMS, the two most common histologies in soft tissue sarcoma, there are limited treatment options that readily balance efficacy and toxicity. Patients (pts) tre... read more here.
Keywords: study combination; liposarcoma lps; combination lenvatinib; lenvatinib eribulin ... See more keywords